Researcher

Verena Lohr
Phone:+49 391 6110 210
Email:lohr@...

Sandtorstrasse 1, 39106 Magdeburg, Germany

Additional Information

Collaborations:
ARB Group (Dr. Steffen Klamt);

Dr. Ingo Jordan, Dr. Volker Sandig, ProBioGen AG, Berlin, Germany;

Prof. Dr. Gerd Sutter, Virology Department LMU Munich, Germany;

Dr. Dietmar Katinger, Polymun AG, Vienna, Austria;

Prof. Amine Kamen, Biotechnology Department NRC, Montréal, Canada

Start:
2008/06/01

End: April 2013

Characterization of Growth, Metabolism and Product Formation of Avian Designer Cells

Characterization of Growth, Metabolism and Product Formation of Avian Designer Cells

Motivation

Newly developed designer cells as alternatives to established cell lines such as MDCK or Vero cells are currently under investigation for vaccine production. Potential candidates are the duck cell lines AGE1.CR.pIX® and its progenitor AGE1.CR®, developed and kindly provided by ProBioGen AG. Both cells are adapted to proliferation in suspension in chemically defined media to simplify manufacturing processes [1].
There are several options for vaccination, i.e. the use of vaccines that consist of a whole virus or virus parts to induce immunity, or the use of vaccines that consist of a vector which carries certain genes to induce immunity.
An example of a vaccine where the virus itself is used as a vaccinating agent is the influenza vaccine. On the other hand, a promising vector to deliver vaccinating agents against different diseases (e.g. malaria or tuberculosis) is the highly attenuated Modified Vaccinia Virus Ankara (MVA), which is used for smallpox vaccination [2]. Due to a number of deletions and mutations, the host range of this virus is restricted to avian cells. For this reason, an avian cell line is desirable for vaccine manufacturing.

To characterize the potential of the duck AGE1.CR® cell lines, influenza virus and MVA are used as model viruses in this project [3].

Scheme of production and application of recombinant MVA for infection studies. Zoom Image
Scheme of production and application of recombinant MVA for infection studies.

Work contents

To use the full potential of new cell lines and to support design of manufacturing processes, comprehensive studies with different viruses are required. Different seasonal influenza A and B virus strains and cold adapted viruses provided by Polymun AG are tested. In addition, wildtype MVA and fluorophore labeled MVA strains, e.g. a recombinant MVA strain expressing GFP (kindly provided by Prof. Sutter, LMU Munich), are used. To characterize production cell lines as thorough as possible, a broad range of methods and assays are used. These include:

  • different cultivation systems,
  • cellular metabolism (including metabolic flux analysis),
  • dynamics of virus replication and
  • flow cytometric analysis.

The latter technique is used to monitor changes in cell cycle, induction of apoptosis and progress of infection. Using the GFP expressing MVA strain, monitoring the infection within the cell population is highly simplified.

Laser-scanning microscope picture (LSM 510, Zeiss, 100x) of AGE1.CR.pIX cells expressing GFP after infection with MVA-egfp (cells which are infected and produce virus are green). Zoom Image
Laser-scanning microscope picture (LSM 510, Zeiss, 100x) of AGE1.CR.pIX cells expressing GFP after infection with MVA-egfp (cells which are infected and produce virus are green). [less]
Eplication dynamics of influenza virus change (HA titer (squares)) while adapting the influenza virus to the AGE1.CR.pIX producer cell line during some passages. Zoom Image
Eplication dynamics of influenza virus change (HA titer (squares)) while adapting the influenza virus to the AGE1.CR.pIX producer cell line during some passages. [less]

References

[1] Jordan I, Vos A, Beilfuß S, Neubert A, Breul S, Sandig V (2009): An avian cell line designed for production of highly attenuated viruses. Vaccine 27:748-756.
[2] Moss B. "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety". Proc Natl Acad Sci U S A 1996;93(21):11341-8.
[3] Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U (2009): New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagation. Vaccine 27: 4975-4982.

Related projects


Process Characterisation and Optimisation for a Recombinant Protein Produced by a Novel Human Designer Cell Line
Viral Glycocalix in Dependence on Host Cell Line, Influenza Virus Strain and Production Process Parameters
Flow Cytometric Analysis of Virus-induced Apoptosis and Virus Replication
Analysis and Redesign of Biological Networks

 
loading content
Go to Editor View